Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug;37(4):933-936.
doi: 10.1007/s00455-021-10354-9. Epub 2021 Aug 16.

Is There a Role for Topical Swallowed Steroids upon Emergency Room Admission for Suspected Food Bolus Obstruction in Eosinophilic Esophagitis?

Philipp Schreiner  1 , Thomas Greuter  2 , Aurora Tatu  2 , Dagmar I Keller  3 , Alex Straumann  2 , Luc Biedermann  2
Affiliations

Is There a Role for Topical Swallowed Steroids upon Emergency Room Admission for Suspected Food Bolus Obstruction in Eosinophilic Esophagitis?

Philipp Schreiner et al. Dysphagia. 2022 Aug.

Abstract

Since most pharmacological treatments in case of esophageal food impaction (EFI) are unsuccessful, an endoscopy is usually required to resolve EFI. We present the first results of a budesonide orodispersible tablet (BOT) as a medical treatment option before endoscopy. We evaluated all patients with a suspected EFI to receive BOT before emergent endoscopy at a tertiary hospital between March 2019 and June 2020. A total of eight patients received BOT before endoscopy. Mean age was 50.1 years and 87.5% were male. In 38% (3/8) of patients the EFI resolved without endoscopic intervention. No adverse events occurred. After endoscopy, a diagnosis of EoE was established in 75%. This case series demonstrate the potential of BOT as medical rescue therapy in case of EFI.

Keywords: Budesonide orodispersible tablet; Deglutition; Deglutition disorders; Esophageal food impaction.

PubMed Disclaimer

Conflict of interest statement

PS received consulting fees from Pfizer, Takeda and Janssen-Cilag and travel support from Falk, UCB and Pfizer. TG has consulting contracts with Sanofi-Regeneron and Falk Pharma GmbH, received travel grants from Falk Pharma GmbH and Vifor, and an unrestricted research grant from Novartis. AT has no conflict of interest. DIK has no conflict of interest. AS reports receiving consulting fees from Allakos, AstraZeneca, EsoCap, Dr. Falk Pharma, Gossamer, GSK, Receptos-Celgene and Regeneron-Sanofi. LB received consulting fees and/or speaker fees and/or research grants from Dr. Falk Pharma, GmbH, Germany, Vifor AG, Switzerland, Esocap AG, Switzerland, Sanofi-Aventis AG, Switzerland and Calypso Biotech SA.

Figures

Fig. 1
Fig. 1
Flow chart
See this image and copyright information in PMC

References

    1. Sengupta N, Tapper EB, Corban C, Sommers T, Leffler DA, Lembo AJ. The clinical predictors of aetiology and complications among 173 patients presenting to the Emergency Department with oesophageal food bolus impaction from 2004–2014. Aliment Pharmacol Ther. 2015;42(1):91–98. doi: 10.1111/apt.13237. - DOI - PubMed
    1. Schupack DA, Lenz CJ, Geno DM, Tholen CJ, Leggett CL, Katzka DA, Alexander JA. The evolution of treatment and complications of esophageal food impaction. U Eur Gastroenterol J. 2019;7(4):548–556. doi: 10.1177/2050640619836052. - DOI - PMC - PubMed
    1. Peksa GD, DeMott JM, Slocum GW, Burkins J, Gottlieb M. Glucagon for relief of acute esophageal foreign bodies and food impactions: a systematic review and meta-analysis. Pharmacotherapy. 2019;39(4):463–472. doi: 10.1002/phar.2236. - DOI - PubMed
    1. Willenbring BA, Schnitker CK, Stellpflug SJ. Oral nitroglycerin solution may be effective for esophageal food impaction. J Emerg Med. 2018;54(5):678–680. doi: 10.1016/j.jemermed.2018.01.024. - DOI - PubMed
    1. Lucendo AJ, Miehlke S, Schlag C, Vieth M, von Arnim U, Molina-Infante J, Hartmann D, Bredenoord AJ, Ciriza de Los Rios C, Schubert S, Bruckner S, Madisch A, Hayat J, Tack J, Attwood S, Mueller R, Greinwald R, Schoepfer A, Straumann A, International EOSSG Efficacy of budesonide orodispersible tablets as induction therapy for eosinophilic esophagitis in a randomized placebo-controlled trial. Gastroenterology. 2019;157(1):74–86 e15. doi: 10.1053/j.gastro.2019.03.025. - DOI - PubMed

Publication types

Supplementary concepts